As expected, genes including 53BP1 and PAXIP1 previously identified in murine models as synthetically viable in BRCA1/BRCA2-deficient tumors were not frequently altered in human cancers (Additional file 1: Fig. S2a-c) [53, 54]. The gene discussed is TP53BP1; the disease is cancer.